TAK-653

Investigational Nootropic

Experimental positive allosteric modulator of AMPA receptors studied in cellular and animal models. Human safety, efficacy, dosing, and pharmacokinetics are not established by the retained evidence.

Pharmacokinetic model

A route-level PK model for tak-653 is being prepared from published data. Dosing references, studies, and documented interactions are below; the app catalog is updated as models are validated.

Key facts

Category: Investigational Nootropic
Suggested cadence: once daily

Research behind this entry

TAK-653, an AMPA receptor potentiator with minimal agonistic activity, produces an antidepressant-like effect with a favorable safety profile in rats Hara H, Suzuki A, Kunugi A, Tajima Y, Yamada R, Kimura H · Pharmacology, Biochemistry and Behavior, 2021 DOI
Rat behavioral and safety experiments characterized TAK-653 as an AMPA-receptor potentiator with limited agonistic activity. These preclinical results do not establish human antidepressant efficacy.
Strictly regulated agonist-dependent activation of AMPA-R is the key characteristic of TAK-653 for robust synaptic responses and cognitive improvement Suzuki A, Kunugi A, Tajima Y, Suzuki N, Suzuki M, Toyofuku M, Kuno H, Sogabe S, Kosugi Y, Awasaki Y, Kaku T, Kimura H · Scientific Reports, 2021 DOI
Cellular and animal experiments examined agonist-dependent AMPA potentiation and cognitive-task performance. They do not provide human dosing, clinical efficacy, or validated human PK.

2 published studies referenced in the app, each with a plain-language summary.